4.7 Review

Molecular strategies for the utilisation of human milk oligosaccharides by infant gut-associated bacteria

期刊

FEMS MICROBIOLOGY REVIEWS
卷 47, 期 6, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/femsre/fuad056

关键词

human milk oligosaccharides; prebiotics; infant gut microbiota; probiotics; Bifidobacteria; Lactobacillus

向作者/读者索取更多资源

The abundance of certain bacteria in the feces of breast-fed infants is due to their ability to metabolize human milk oligosaccharides (HMOs). HMOs are complex sugars that reach the infant's intestine intact and serve as a fermentable substrate for specific intestinal microbes. These microbes possess the genes and enzymes necessary for HMO degradation. The degraded HMOs can also be utilized by other gut bacteria.
A number of bacterial species are found in high abundance in the faeces of healthy breast-fed infants, an occurrence that is understood to be, at least in part, due to the ability of these bacteria to metabolize human milk oligosaccharides (HMOs). HMOs are the third most abundant component of human milk after lactose and lipids, and represent complex sugars which possess unique structural diversity and are resistant to infant gastrointestinal digestion. Thus, these sugars reach the infant distal intestine intact, thereby serving as a fermentable substrate for specific intestinal microbes, including Firmicutes, Proteobacteria, and especially infant-associated Bifidobacterium spp. which help to shape the infant gut microbiome. Bacteria utilising HMOs are equipped with genes associated with their degradation and a number of carbohydrate-active enzymes known as glycoside hydrolase enzymes have been identified in the infant gut, which supports this hypothesis. The resulting degraded HMOs can also be used as growth substrates for other infant gut bacteria present in a microbe-microbe interaction known as 'cross-feeding'. This review describes the current knowledge on HMO metabolism by particular infant gut-associated bacteria, many of which are currently used as commercial probiotics, including the distinct strategies employed by individual species for HMO utilisation. This review describes the current knowledge on HMO metabolism by a range of infant gut-associated bacteria, many of which are currently used as commercial probiotics, including the distinct strategies employed by individual species for HMO utilisation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据